Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis [4]

Leukemia

Volumn 18, Issue 5, 2004, Pages 1027-1029

  Elliott, M A ^a   Pardanani, A ^a   Li, C Y ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; BONE MARROW BIOPSY; CASE REPORT; DIAGNOSTIC IMAGING; DISEASE DURATION; DRUG EFFICACY; EOSINOPHILIA; FLOW CYTOMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LABORATORY TEST; LETTER; LEUKEMIA REMISSION; MALE; MAST CELL; OUTCOMES RESEARCH; PANCYTOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYMPTOMATOLOGY; SYSTEMIC MASTOCYTOSIS; BONE MARROW CELL; IMMUNOLOGY; PATHOLOGY;

ADULT; BONE MARROW CELLS; EOSINOPHILIA; HUMANS; IMMUNOPHENOTYPING; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; PIPERAZINES; PYRIMIDINES;

EID: 2342532361     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403329     Document Type: Letter

References (6)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
2. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-1578.
3. Pardanani A, Elliott M, Reeder T, Li C-Y, Baxter EJ, Cross NCP et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535-536.
4. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
5. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 2003; 102: 3093-3096.
6. Pardanani A, Kimlinger TK, Reeder TL, Li CY, Tefferi A. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol 2003; 120: 691-694.